Monitoring American Healthcare REIT Inc (AHR) after recent insider movements

Daniel Torres

American Healthcare REIT Inc’s recent filing unveils that its Director Hanson Jeffrey T unloaded Company’s shares for reported $1.72 million on Dec 22 ’25. In the deal valued at $48.38 per share,35,570 shares were sold. As a result of this transaction, Hanson Jeffrey T now holds 19,208 shares worth roughly $0.92 million.

Then, Hanson Jeffrey T sold 19,208 shares, generating $929,690 in total proceeds. Upon selling the shares at $48.40, the Director now owns 0 shares.

Before that, Jeffrey Hanson bought 54,778 shares. American Healthcare REIT Inc shares valued at $2,649,904 were divested by the Director at a price of $48.38 per share.

UBS initiated its American Healthcare REIT Inc [AHR] rating to a Buy in a research note published on September 19, 2025; the price target was $51. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid July with a ‘”an Outperform”‘ rating. Scotiabank began covering AHR with “Sector outperform” recommendation on June 30, 2025. Jefferies started covering the stock on April 28, 2025. It rated AHR as “a Buy”.

Price Performance Review of AHR

On Tuesday, American Healthcare REIT Inc [NYSE:AHR] saw its stock jump 0.42% to $47.74. Over the last five days, the stock has gained 1.29%. American Healthcare REIT Inc shares have risen nearly 75.39% since the year began. Nevertheless, the stocks have risen 1.44% over the past one year.

How much short interest is there in American Healthcare REIT Inc?

A steep rise in short interest was recorded in American Healthcare REIT Inc stocks on 2025-12-31, growing by 5.19 million shares to a total of 18.59 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 13.39 million shares. There was a rise of 27.94%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on March 14, 2024 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $18 price target.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.